Bio-Rad Laboratories, a global leader in clinical diagnostics and life science research, has formally announced the expansion of its Pioneer Antibody Discovery Platform services to encompass the rapid generation and screening of bispecific antibodies using its proprietary SpyLock Technology. This enhancement builds on the existing capabilities of the Pioneer Platform, which features a fully human synthetic phage display library of 225 billion unique Fab antibodies and the SpyDisplay technology. The platform is designed to deliver high-quality antibody candidates quickly and is supported by a comprehensive suite of customizable discovery services. This expansion aims to accelerate the identification of effective antibody combinations for development, particularly in fields such as immuno-oncology and infectious diseases.
In 2023, Bio-Rad Laboratories, headquartered in Hercules, California, reported $2.7 billion in revenue. The company employs approximately 8,000 individuals across its global network of manufacturing, research, development, and sales operations. Bio-Rad collaborates with various organizations worldwide, including a notable partnership with Salipro Biotech, which has successfully generated novel human antibodies against challenging GPCR targets. The addition of SpyLock to the Pioneer Platform underscores Bio-Rad’s commitment to advancing scientific research and providing innovative solutions that enhance therapeutic efficacy and support the rapid development of bispecific antibodies.
